UK Markets closed

Worldwide Companion Diagnostics Industry to 2026 - Featuring Agilent Technologies, BioMerieux and Myriad Genetics Among Others

·6-min read

Dublin, Oct. 06, 2021 (GLOBE NEWSWIRE) -- The "Companion Diagnostics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

The global companion diagnostics market exhibited strong growth during 2015-2020. Looking forward, the market is expected to grow at a CAGR of 19.5% during 2021-2026. Keeping in mind the uncertainties of COVID-19, the analyst is continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

Companion diagnostics refer to a combination of tests and therapies that provide essential information about corresponding therapeutic products to deliver safe and effective medical care. These diagnostics also offer an in-depth understanding of disease biology and the mechanism of action (MOA), which help healthcare professionals determine the potential side effects or risks of a therapeutic product on the patient. At present, companion diagnostics are extensively utilized in oncology to deliver targeted therapies and personalized medicines to patients.

The growing prevalence of cancer, in confluence with the escalating demand for in-vitro diagnostics and targeted therapies, represents one of the key factors impelling the global companion diagnostics market growth. Apart from this, personalized healthcare (PHC) and precision medicine are also gaining traction in the treatment of cardiovascular, neurological, infectious and inflammatory diseases, which, in turn, is bolstering the growth of the market. Furthermore, the escalating demand for next-generation sequencing (NGS), the rising number of clinical trials and the increasing focus on the co-development of drugs and diagnostic technologies are contributing to the market growth. The introduction of new biomarkers, rising approvals of companion diagnostics and increasing collaboration between companies to develop novel companion diagnostic products are some of the other factors positively influencing the market growth. Currently, due to the spread of the coronavirus disease (COVID-19), diagnostic service providers are providing test services to healthcare providers. They are also utilizing companion diagnostics to detect the efficacy of COVID-19 drugs among patients undergoing oncology therapies.

Key Market Segmentation

The analyst provides an analysis of the key trends in each sub-segment of the global companion diagnostics market, along with forecasts at the global, regional and country level from 2021-2026. The report has categorized the market based on region, product & services, technology, indication and end-user.

Breakup by Product & Service

  • Assays, Kits and Reagents

  • Software and Services

Breakup by Technology

  • Immunohistochemistry (IHC)

  • Polymerase Chain Reaction (PCR)

  • In-situ Hybridization (ISH)

  • Real-time PCR (RT-PCR)

  • Gene Sequencing

  • Others

Breakup by Indication

  • Cancer

  • Lung Cancer

  • Breast Cancer

  • Colorectal Cancer

  • Gastric Cancer

  • Melanoma

  • Others

  • Neurological Diseases

  • Infectious Diseases

  • Cardiovascular Diseases

  • Others

Breakup by End User

  • Pharmaceutical & Biopharmaceutical Companies

  • Reference Laboratories

  • Contract Research Organizations

  • Others

Breakup by Region

  • North America

  • United States

  • Canada

  • Asia Pacific

  • China

  • Japan

  • India

  • South Korea

  • Australia

  • Indonesia

  • Others

  • Europe

  • Germany

  • France

  • United Kingdom

  • Italy

  • Spain

  • Russia

  • Others

  • Latin America

  • Brazil

  • Mexico

  • Others

  • Middle East and Africa

Competitive Landscape

The report has also analysed the competitive landscape of the market with some of the key players being Abbott Laboratories, Agilent Technologies, BioMerieux, Danaher Corporation, Roche Holding AG, Myriad Genetics Inc., Siemens Healthcare and Thermo Fisher Scientific Inc.

Key Topics Covered:

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction
4.1 Overview
4.2 Key Industry Trends

5 Global Companion Diagnostics Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Product & Service
6.1 Assays, Kits and Reagents
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Software and Services
6.2.1 Market Trends
6.2.2 Market Forecast

7 Market Breakup by Technology
7.1 Immunohistochemistry (IHC)
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Polymerase Chain Reaction (PCR)
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 In-situ Hybridization (ISH)
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Real-time PCR (RT-PCR)
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 Gene Sequencing
7.5.1 Market Trends
7.5.2 Market Forecast
7.6 Others
7.6.1 Market Trends
7.6.2 Market Forecast

8 Market Breakup by Indication
8.1 Cancer
8.1.1 Market Trends
8.1.2 Major Types
8.1.2.1 Lung Cancer
8.1.2.2 Breast Cancer
8.1.2.3 Colorectal Cancer
8.1.2.4 Gastric Cancer
8.1.2.5 Melanoma
8.1.2.6 Others
8.1.3 Market Forecast
8.2 Neurological Diseases
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Infectious Diseases
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Cardiovascular Diseases
8.4.1 Market Trends
8.4.2 Market Forecast
8.5 Others
8.5.1 Market Trends
8.5.2 Market Forecast

9 Market Breakup by End-user
9.1 Pharmaceutical & Biopharmaceutical Companies
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 Reference Laboratories
9.2.1 Market Trends
9.2.2 Market Forecast
9.3 Contract Research Organizations
9.3.1 Market Trends
9.3.2 Market Forecast
9.4 Others
9.4.1 Market Trends
9.4.2 Market Forecast

10 Market Breakup by Region

11 SWOT Analysis

12 Value Chain Analysis

13 Porters Five Forces Analysis

14 Price Analysis

15 Competitive Landscape
15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
15.3.1 Abbott Laboratories
15.3.1.1 Company Overview
15.3.1.2 Product Portfolio
15.3.1.3 Financials
15.3.1.4 SWOT Analysis
15.3.2 Agilent Technologies
15.3.2.1 Company Overview
15.3.2.2 Product Portfolio
15.3.2.3 Financials
15.3.2.4 SWOT Analysis
15.3.3 BioMerieux
15.3.3.1 Company Overview
15.3.3.2 Product Portfolio
15.3.3.3 Financials
15.3.3.4 SWOT Analysis
15.3.4 Danaher Corporation
15.3.4.1 Company Overview
15.3.4.2 Product Portfolio
15.3.4.3 Financials
15.3.4.4 SWOT Analysis
15.3.5 Roche Holding AG
15.3.5.1 Company Overview
15.3.5.2 Product Portfolio
15.3.5.3 SWOT Analysis
15.3.6 Myriad Genetics Inc.
15.3.6.1 Company Overview
15.3.6.2 Product Portfolio
15.3.6.3 Financials
15.3.6.4 SWOT Analysis
15.3.7 Siemens Healthcare
15.3.7.1 Company Overview
15.3.7.2 Product Portfolio
15.3.7.3 Financials
15.3.7.4 SWOT Analysis
15.3.8 Thermo Fisher Scientific Inc.
15.3.8.1 Company Overview
15.3.8.2 Product Portfolio
15.3.8.3 Financials
15.3.8.4 SWOT Analysis

For more information about this report visit https://www.researchandmarkets.com/r/fxloat

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting